Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors.

AIM Currently, little is known about differences in miRNA expression between KIT/PDGFRA mutant and KIT/PDGFRA wild-type (WT)-SDH deficient gastrointestinal stromal tumors (GIST). This prompted us to perform an integrated multiple expression profile of miRNA and mRNA, constructing an original miRNA-mRNA regulatory network in KIT/PDGFRA WT-SDH deficient GIST patients. PATIENTS & METHODS Analyses were carried out on KIT/PDGFRA mutant versus KIT/PDGFRA WT-SDH deficient GIST. Genome-wide miRNA and gene-expression analysis were performed using Agilent Human miRNA microarray and Affimetrix array, respectively. RESULTS Three potential regulatory networks (IGF1R → miR-139-5p/miR-455/let-7b, cyclin-dependent kinase 6 (CDK6) → miR-139-5p/let-7b and CD44 → miR-330-3p) were identified. CONCLUSION The miR-139-5p, 455-5p and let-7b signature, in particular, may represent an important therapeutic target in KIT/PDGFRA WT-SDH deficient GIST, usually characterized by IGF1R overexpression.

[1]  S. Efroni,et al.  MicroRNA regulation of molecular pathways as a generic mechanism and as a core disease phenotype , 2015, Oncotarget.

[2]  M. Heinrich,et al.  Quadruple wild-type (WT) GIST: defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways , 2014, Cancer medicine.

[3]  K. Esser,et al.  Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis. , 2011, Physiological genomics.

[4]  Xiong Guo,et al.  Let-7b-5p regulates proliferation and apoptosis in multiple myeloma by targeting IGF1R. , 2014, Acta biochimica et biophysica Sinica.

[5]  Xiaolong Wang,et al.  IGF-1R, a target of let-7b, mediates crosstalk between IRS-2/Akt and MAPK pathways to promote proliferation of oral squamous cell carcinoma , 2014, Oncotarget.

[6]  L. Kang,et al.  Quantitative and Qualitative Analysis of Flavonoids and Phenolic Acids in Snow Chrysanthemum (Coreopsis tinctoria Nutt.) by HPLC-DAD and UPLC-ESI-QTOF-MS , 2016, Molecules.

[7]  V. Orian-Rousseau.  CD44, a therapeutic target for metastasising tumours. , 2010, European journal of cancer.

[8]  Jingqing Yang,et al.  The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. , 2005, Cancer research.

[9]  S. Angelini,et al.  miRNA profiling in gastrointestinal stromal tumors: implication as diagnostic and prognostic markers. , 2015, Epigenomics.

[10]  P. Hrelia,et al.  Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis , 2015, International journal of molecular sciences.

[11]  K. Xue,et al.  MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. , 2015, International journal of clinical and experimental pathology.

[12]  G. Shapiro,et al.  Targeting CDK4 and CDK6: From Discovery to Therapy. , 2016, Cancer discovery.

[13]  M. Pantaleo,et al.  Gastrointestinal cancer: Management of GIST—go beyond imatinib: treat resistant subtypes , 2015, Nature Reviews Clinical Oncology.

[14]  Y. Shan,et al.  Significance of CD44 Expression in Gastrointestinal Stromal Tumors in Relation to Disease Progression and Survival , 2007, World Journal of Surgery.

[15]  M. Heinrich,et al.  Insulin‐like growth factor 1 receptor expression in wild‐type GISTs: A potential novel therapeutic target , 2009, International journal of cancer.

[16]  J. Fletcher,et al.  Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy. , 2013, Pharmacogenomics.

[17]  Ling Fang,et al.  Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis , 2010, Nucleic acids research.

[18]  E. Sontheimer,et al.  Origins and Mechanisms of miRNAs and siRNAs , 2009, Cell.

[19]  W. Kim,et al.  ETV1 mRNA is specifically expressed in gastrointestinal stromal tumors , 2015, Virchows Archiv.

[20]  K. Chaudhuri,et al.  MicroRNA detection and target prediction: integration of computational and experimental approaches. , 2007, DNA and cell biology.

[21]  L. Qin,et al.  CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers , 2012, Genes, chromosomes & cancer.

[22]  G. Brandi,et al.  Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST) , 2014, BMC Cancer.

[23]  R. Casadio,et al.  Expression of IGF-1 receptor in KIT/PDGF receptor-α wild-type gastrointestinal stromal tumors with succinate dehydrogenase complex dysfunction. , 2013, Future oncology.

[24]  P. Hrelia,et al.  Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia , 2016, Expert opinion on drug metabolism & toxicology.

[25]  P. Marynen,et al.  Efficacy of the Kinase Inhibitor SU11248 against Gastrointestinal Stromal Tumor Mutants Refractory to Imatinib Mesylate , 2006, Clinical Cancer Research.

[26]  A. Astolfi,et al.  Insulin-like Growth Factor (IGF) system and gastrointestinal stromal tumours (GIST): present and future. , 2014, Histology and histopathology.

[27]  J. Barretina,et al.  Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification , 2010, International journal of cancer.

[28]  Jianwen Liu,et al.  MiR-139 inhibits invasion and metastasis of colorectal cancer by targeting the type I insulin-like growth factor receptor. , 2012, Biochemical pharmacology.

[29]  R. Weinberg,et al.  Growth-Inhibitory and Tumor- Suppressive Functions of p53 Depend on Its Repression of CD44 Expression , 2008, Cell.

[30]  J. Fletcher,et al.  Biology of gastrointestinal stromal tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.